Table 4. Secondary end points (shown are... | American Society of Hematology

Table 4.

Secondary end points (shown are results in the acyclovir group versus the placebo group)

	Modified intent-to-treat analysis
End point^*	HR	95% CI	P
Survival†
By 1 year	0.43	0.16, 1.1	.07
By 2 years	0.65	0.29, 1.5	.30
By 3 years	0.58	0.27, 1.2	.15
By 5 years	0.55	0.26, 1.2	.11
VZV-free survival†
By 1 year	0.33	0.14, 0.74	.005
By 2 years	0.59	0.31, 1.1	.10
By 3 years	0.61	0.34, 1.1	.09
By 5 years	0.64	0.37, 1.1	.10
Chronic GVHD by 1 year	1.4	0.68, 0.29	.36
HSV infection by 1 year	0.64	0.21, 2.0	.42
CMV disease by 1 year	1.2	0.31, 4.3	.84

	Modified intent-to-treat analysis
End point^*	HR	95% CI	P
Survival†
By 1 year	0.43	0.16, 1.1	.07
By 2 years	0.65	0.29, 1.5	.30
By 3 years	0.58	0.27, 1.2	.15
By 5 years	0.55	0.26, 1.2	.11
VZV-free survival†
By 1 year	0.33	0.14, 0.74	.005
By 2 years	0.59	0.31, 1.1	.10
By 3 years	0.61	0.34, 1.1	.09
By 5 years	0.64	0.37, 1.1	.10
Chronic GVHD by 1 year	1.4	0.68, 0.29	.36
HSV infection by 1 year	0.64	0.21, 2.0	.42
CMV disease by 1 year	1.2	0.31, 4.3	.84

Years refer to year after transplantation

Hazard ratios less than 1 indicate improved survival relative to placebo